Literature DB >> 27511456

Quantification of intact plasma AGT consisting of oxidized and reduced conformations using a modified ELISA.

Ryousuke Satou1, Hiroyuki Kobori2, Akemi Katsurada3, Kayoko Miyata3, L Gabriel Navar3.   

Abstract

The pleiotropic actions of the renin-angiotensin system (RAS) depend on the availability of angiotensinogen (AGT) which generates angiotensin I (ANG I) when cleaved by renin. Thus, quantification of the intact AGT (iAGT) concentrations is important to evaluate the actual renin substrate available. The iAGT conformation exists as oxidized AGT (oxi-AGT) and reduced AGT (red-AGT) in a disulfide bond, and oxi-AGT has a higher affinity for renin, which may exacerbate RAS-associated diseases. Accordingly, we determined iAGT, oxi-AGT, and red-AGT levels in plasma from rats and mice. Blood samples were obtained by cardiac puncture and then immediately mixed with an inhibitor solution containing a renin inhibitor. Total AGT (tAGT) levels were measured by tAGT ELISA which detects both cleaved and iAGT. iAGT levels were determined by iAGT ELISA which was found to only detect red-AGT. Thus, it was necessary to treat samples with dithiothreitol, a reducing agent, to quantify total iAGT concentration. tAGT levels in rat and mouse plasma were 1,839 ± 139 and 1,082 ± 77 ng/ml, respectively. iAGT levels were 53% of tAGT in rat plasma but only 22% in mouse plasma, probably reflecting the greater plasma renin activity in mice. The ratios of oxi-AGT and red-AGT were ∼4:1 (rat) and 16:1 (mouse). Plasma iAGT consists of oxi-AGT and red-AGT, suggesting that oxidative stress can influence ANG I generation by the AGT conformation switch. Furthermore, the lower availability of plasma iAGT in mice suggests that it may serve as a limiting factor in ANG I formation in this species.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  ELISA; intact AGT; plasma RAS; renin-angiotensin system

Mesh:

Substances:

Year:  2016        PMID: 27511456      PMCID: PMC5210198          DOI: 10.1152/ajprenal.00320.2016

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  22 in total

1.  Interferon-γ biphasically regulates angiotensinogen expression via a JAK-STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells.

Authors:  Ryousuke Satou; Kayoko Miyata; Romer A Gonzalez-Villalobos; Julie R Ingelfinger; L Gabriel Navar; Hiroyuki Kobori
Journal:  FASEB J       Date:  2012-02-01       Impact factor: 5.191

2.  Overexpression of mouse angiotensinogen in renal proximal tubule causes salt-sensitive hypertension in mice.

Authors:  Jian Ying; Deborah Stuart; Elaine Hillas; Barbu R Gociman; Nirupama Ramkumar; Jean-Marc Lalouel; Donald E Kohan
Journal:  Am J Hypertens       Date:  2012-03-01       Impact factor: 2.689

Review 3.  Regulation of intrarenal angiotensin II in hypertension.

Authors:  L Gabriel Navar; Lisa M Harrison-Bernard; Akira Nishiyama; Hiroyuki Kobori
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

4.  Haplotypes of angiotensinogen in essential hypertension.

Authors:  X Jeunemaitre; I Inoue; C Williams; A Charru; J Tichet; M Powers; A M Sharma; A P Gimenez-Roqueplo; A Hata; P Corvol; J M Lalouel
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

Review 5.  The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease.

Authors:  Hiroyuki Kobori; Masaomi Nangaku; L Gabriel Navar; Akira Nishiyama
Journal:  Pharmacol Rev       Date:  2007-09       Impact factor: 25.468

6.  Determination of plasma and urinary angiotensinogen levels in rodents by newly developed ELISA.

Authors:  Hiroyuki Kobori; Akemi Katsurada; Kayoko Miyata; Naro Ohashi; Ryousuke Satou; Toshie Saito; Yoshiaki Hagiwara; Kazuya Miyashita; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2008-03-19

7.  Sequential activation of the reactive oxygen species/angiotensinogen/renin-angiotensin system axis in renal injury of type 2 diabetic rats.

Authors:  Kayoko Miyata; Naro Ohashi; Yuki Suzaki; Akemi Katsurada; Hiroyuki Kobori
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-04-21       Impact factor: 2.557

8.  RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney.

Authors:  S Sachetelli; Q Liu; S-L Zhang; F Liu; T-J Hsieh; M-L Brezniceanu; D-F Guo; J G Filep; J R Ingelfinger; C D Sigmund; P Hamet; J S D Chan
Journal:  Kidney Int       Date:  2006-03       Impact factor: 10.612

9.  Improved Assay for Quantifying a Redox Form of Angiotensinogen as a Biomarker for Pre-Eclampsia: A Case-Control Study.

Authors:  Soheila Rahgozar; Tayebeh Amirian; Miao Qi; Zahra Shahshahan; Mansureh Entezar-E-Ghaem; Hatav Ghasemi Tehrani; Mehran Miroliaei; Steven A Krilis; Bill Giannakopoulos
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

10.  A redox switch in angiotensinogen modulates angiotensin release.

Authors:  Aiwu Zhou; Robin W Carrell; Michael P Murphy; Zhenquan Wei; Yahui Yan; Peter L D Stanley; Penelope E Stein; Fiona Broughton Pipkin; Randy J Read
Journal:  Nature       Date:  2010-10-06       Impact factor: 49.962

View more
  3 in total

1.  Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.

Authors:  T Cooper Woods; Ryousuke Satou; Kayoko Miyata; Akemi Katsurada; Courtney M Dugas; Natasha C Klingenberg; Vivian A Fonseca; L Gabriel Navar
Journal:  Am J Nephrol       Date:  2019-03-28       Impact factor: 3.754

2.  HDAC9 is an epigenetic repressor of kidney angiotensinogen establishing a sex difference.

Authors:  Camille T Bourgeois; Ryousuke Satou; Minolfa C Prieto
Journal:  Biol Sex Differ       Date:  2017-05-30       Impact factor: 5.027

3.  Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.

Authors:  Takuo Yoshimoto; Takayuki Furuki; Hiroyuki Kobori; Masaaki Miyakawa; Hitomi Imachi; Koji Murao; Akira Nishiyama
Journal:  J Investig Med       Date:  2017-06-08       Impact factor: 2.895

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.